Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pathogenitätsfaktoren von Staphylococcus Pettenkoferi bei Fußwunden und Osteitis bei Diabetikern (PETTENK-OS)

22. September 2026 aktualisiert von: Centre Hospitalier Universitaire de Nīmes

Bewertung der Pathogenitätsfaktoren von Staphylococcus Pettenkoferi bei Fußwunden und Osteitis bei Diabetikern. Die PETTENK-OS-Studie

Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.

At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.

Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.

A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.

Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

230

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Gard
      • Nîmes, Gard, Frankreich, 30029
        • Nîmes University Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.

Beschreibung

Inclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Exclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: OTHER

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Zeitfenster: Day 0 to 3 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms).

Day 0 to 3 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Zeitfenster: 3 - 6 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances.

3 - 6 months
Resistome in the strain population according to sample origin:osteitis
Zeitfenster: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: blood cultures
Zeitfenster: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: osteitis
Zeitfenster: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: blood cultures
Zeitfenster: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: osteitis
Zeitfenster: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Zeitfenster: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: diabetic wounds
Zeitfenster: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: blood cultures
Zeitfenster: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: nasal carriage
Zeitfenster: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Phenotypic resistance profiles in the population in a subsample of 85 strains
Zeitfenster: 6 - 14 months

The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Zeitfenster: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Zeitfenster: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Zeitfenster: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Zeitfenster: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Zeitfenster: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Zeitfenster: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Zeitfenster: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Zeitfenster: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Zeitfenster: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Zeitfenster: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Zeitfenster: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Zeitfenster: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Zeitfenster: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Zeitfenster: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Zeitfenster: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Zeitfenster: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Zeitfenster: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Zeitfenster: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Zeitfenster: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Zeitfenster: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Zeitfenster: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Zeitfenster: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Zeitfenster: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Zeitfenster: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Zeitfenster: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Zeitfenster: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Zeitfenster: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Zeitfenster: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Chloé MAGNAN, Dr., Nîmes University Hospital, FRANCE

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Januar 2024

Primärer Abschluss (Tatsächlich)

31. Dezember 2025

Studienabschluss (Tatsächlich)

31. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

9. November 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2024

Zuerst gepostet (Tatsächlich)

14. November 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NIMAO/2023-2/CM-01

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .